Novartis Reports Phase 3 extension Data for Dulaglutide in Breast cancer

Novartis today announced Phase 3 extension results for Dulaglutide in patients with Breast cancer. The study demonstrated that Dulaglutide reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Breast cancer and support the continued development of Dulaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Dulaglutide was consistent with previous observations, with no new safety signals identified.